27 completed, 11 recruiting, 9 not yet recruiting, 6 terminated. 15 Not applicable, 13 Phase 1, 8 Phase 2, 4 Phase 4, 2 Phase 3.
Follow Multiple Sclerosis (MS): new trials by email Literature Review of Multiple Sclerosis (MS) trials Research Report on Multiple Sclerosis (MS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Relapsing/Refractory Multiple Sclerosis GT802 Injection - Multiple Sclerosis (MS) | Early Phase 1 | Not yet recruiting | Daishi Tian | 12 | 2026-10-28 | 2026-09-14 |
| Essential Oils for Urinary Symptoms in Multiple Sclerosis Patients Essential Oil Blend (Lavender, Rosemary), Neutral Carrier Oil (Apricot Kernel Oil) - Multiple Sclerosis (MS), Neurogenic Bladder Disorder | Not applicable | Not yet recruiting | University of Oran 1 | 60 | 2026-09-01 | 2026-05-20 |
| My MS Toolkit: An Internet-Based Depression Self-Management Program for Adults Living With Multiple Sclerosis My MS Toolkit - Multiple Sclerosis, Multiple Sclerosis (MS) | Not applicable | Not yet recruiting | University of Washington | 110 | 2026-09-01 | 2026-06-09 |
| TELESM-edu.Nursing: a Personalised Nursing Intervention for People With Multiple Sclerosis TELESM-edu.nursing, Standard - Multiple Sclerosis (MS), Telenursing | Not applicable | Not yet recruiting | G. d'Annunzio University | 110 | 2026-07-01 | 2026-06-11 |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG) | Phase 1 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 18 | 2026-07-01 | 2026-06-30 |
| Serious Game Rehabilitation and Brain Plasticity in MS Serious Game - Multiple Sclerosis (MS) | Not applicable | Not yet recruiting | Lille Catholic University | 40 | 2026-06-01 | 2026-03-16 |
| MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis Multiple Sclerosis (MS), Cerebral Small Vessel Diseases | Recruiting | Oslo University Hospital | 1000 | 2026-05-11 | 2026-06-01 | |
| A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis. Universal STAR-T Cell Injection - Multiple Sclerosis (MS) | Phase 1 | Not yet recruiting | Daishi Tian | 24 | 2026-04-07 | 2026-04-13 |
| Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 1 | Recruiting | Tongji Hospital | 6 | 2026-04-01 | 2026-05-12 |
| A Study of C-CAR168 in the Treatment of Central Nervous System Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD) | Phase 1 | Not yet recruiting | Huashan Hospital | 15 | 2026-02-01 | 2026-01-15 |
| Prevalence of Periodontitis in Egyptian Multiple Sclerosis Patients. Multiple Sclerosis (MS), Periodontal Diseases | Completed | Cairo University | 293 | 2025-09-18 | 2026-03-18 | |
| A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases LCAR-AIO T cells - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disease (NMOSD) | Phase 1 | Withdrawn | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2025-06-17 | 2026-06-24 | |
| Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50 Multiple Sclerosis (MS) | Recruiting | University Hospital, Strasbourg, France | 830 | 2025-02-07 | 2026-01-02 | |
| Pilot of the Virtual Memory Attention and Problem Solving Skills Intervention for Persons With Multiple Sclerosis (MS) Virtual Memory, Attention, and Problem Solving Skills for Persons with MS (MAPSS-MS) - Multiple Sclerosis (MS) | Not applicable | Not yet recruiting | University of Texas at Austin | 34 | 2024-12-01 | 2024-11-29 |
| Enhancing Quality of Life in MS Patients Through Tailored Therapeutic Education Multiple Sclerosis Therapeutic Education Program - Multiple Sclerosis (MS) | Not applicable | Unknown | Akhrif Iman | 50 | 2024-10-05 | 2024-06-10 |
| Mood Disorders in Multiple Sclerosis Patients Multiple Sclerosis (MS), Unipolar Depression | Completed | Islamic Azad University, Sanandaj | 85 | 2024-07-01 | 2024-10-22 | |
| The Effect of Aerobic Exercise on an Elliptical Trainer Versus a Treadmill, in People With Multiple Sclerosis Physical Training - Multiple Sclerosis (MS) | Not applicable | Completed | Soroka University Medical Center | 30 | 2024-06-01 | 2026-01-07 |
| An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden Avonex (IFNβ-1-a, Biogen Netherlands B.V), Rebif (IFNβ-1-a, Merck Europe B.V.), Extavia (IFNβ-1-b, Novartis Europharm Limited) - Multiple Sclerosis (MS) | Active not recruiting | Bayer | 4 | 2024-03-20 | 2026-07-06 | |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells - Systemic Lupus Erythematosus (SLE), Immune-mediated Necrotizing Myopathy (IMNM) | Phase 1 | Recruiting | RenJi Hospital | 30 | 2024-03-20 | 2025-07-25 |
| Increasing Physical Activity for Adults With Multiple Sclerosis (MS) ExerciseRx intervention - Multiple Sclerosis (MS), Fatigue | Not applicable | Unknown | University of Washington | 106 | 2024-02-16 | 2024-02-22 |
Showing 20 of 63. Sign in to see all of them.
Multiple Sclerosis (63) · Multiple Sclerosis, Chronic Progressive (4) · Multiple Sclerosis, Relapsing-Remitting (4) · Myasthenia Gravis (4) · Neuromyelitis Optica (4) · Lupus Erythematosus, Systemic (3) · Scleroderma, Systemic (3) · Alzheimer Disease (2) · Amyotrophic Lateral Sclerosis (2) · Arthritis, Rheumatoid (2) · Autoimmune Diseases (2) · Autoimmune Diseases of the Nervous System (2) · Demyelinating Diseases (2) · Fatigue (2) · Motor Activity (2)
Demyelinating Autoimmune Diseases, CNS (63) · Immune System Diseases (63) · Nervous System Diseases (63) · Autoimmune Diseases (61) · Autoimmune Diseases of the Nervous System (61) · Demyelinating Diseases (61) · Pathological Conditions, Signs and Symptoms (13) · Neuromuscular Diseases (8) · Pathologic Processes (8) · Disease Attributes (7) · Neurodegenerative Diseases (6) · Behavior (5) · Chronic Disease (5) · Cranial Nerve Diseases (5) · Eye Diseases (5)
Interferon beta-1a (2) · elezanumab (2) · ofatumumab (2) · 2019-nCoV Vaccine mRNA-1273 (1) · Ad26COVS1 (1) · Adrenocorticotropic Hormone (1) · Alemtuzumab (1) · BNT162 Vaccine (1) · BNT162b5 (1) · Blood Specimen Collection (1) · COVID-19 Vaccines (1) · Clemastine (1) · Cyclophosphamide (1) · Data Collection (1) · Dietary Fiber (1)
Biogen (3) · University Hospital, Basel, Switzerland (3) · University of Texas Southwestern Medical Center (3) · AbbVie (2) · Assistance Publique - Hôpitaux de Paris (2) · Charite University, Berlin, Germany (2) · Daishi Tian (2) · EMD Serono Research & Development Institute, Inc. (2) · Novartis Pharmaceuticals (2) · University of Washington (2) · Akhrif Iman (1) · American University of Beirut Medical Center (1) · Anokion SA (1) · Ashvattha Therapeutics, Inc. (1) · Assistance Publique Hopitaux De Marseille (1)
United States (23) · France (10) · China (7) · Germany (6) · Canada (5) · Switzerland (5) · United Kingdom (4) · Israel (3) · Poland (3) · Spain (3) · Australia (2) · Austria (2) · Belgium (2) · Croatia (2) · Czechia (2)
Amit Bar-Or, MD, FRCP (1) · Ari J Green, MD, MCR (1) · Brian Hutchinson (1) · Bruno Stankoff, Pr (1) · Chuan Qin (1)
PMID 19073949, PMID 24691080, PMID 28130080, PMID 30928934, PMID 32307769, PMID 33253391, PMID 35641166, PMID 36062026, PMID 36401339, PMID 37012898, PMID 37310119, PMID 39460719, PMID 41268963, PMID 41289027, PMID 41758576
2019 (2), 2018 (1)